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Abstract
The vaccinia virus (VACV) C6 protein has sequence similarities with the poxvirus family Pox_A46, involved in regulation of
host immune responses, but its role is unknown. Here, we have characterized the C6 protein and its effects in virus
replication, innate immune sensing and immunogenicity in vivo. C6 is a 18.2 kDa protein, which is expressed early during
virus infection and localizes to the cytoplasm of infected cells. Deletion of the C6L gene from the poxvirus vector MVA-B
expressing HIV-1 Env, Gag, Pol and Nef antigens from clade B (MVA-B DC6L) had no effect on virus growth kinetics;
therefore C6 protein is not essential for virus replication. The innate immune signals elicited by MVA-B DC6L in human
macrophages and monocyte-derived dendritic cells (moDCs) are characterized by the up-regulation of the expression of
IFN-b and IFN-a/b-inducible genes. In a DNA prime/MVA boost immunization protocol in mice, flow cytometry analysis
revealed that MVA-B DC6L enhanced the magnitude and polyfunctionality of the HIV-1-specific CD4
+ and CD8
+ T-cell
memory immune responses, with most of the HIV-1 responses mediated by the CD8
+ T-cell compartment with an effector
phenotype. Significantly, while MVA-B induced preferentially Env- and Gag-specific CD8
+ T-cell responses, MVA-B DC6L
induced more Gag-Pol-Nef-specific CD8
+ T-cell responses. Furthermore, MVA-B DC6L enhanced the levels of antibodies
against Env in comparison with MVA-B. These findings revealed that C6 can be considered as an immunomodulator and
that deleting C6L gene in MVA-B confers an immunological benefit by enhancing IFN-b-dependent responses and
increasing the magnitude and quality of the T-cell memory immune responses to HIV-1 antigens. Our observations are
relevant for the improvement of MVA vectors as HIV-1 vaccines.
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Introduction
Poxvirus vectors express numerous genes encoding for immu-
nomodulatory proteins that interfere with host anti-viral response
[1]. The VACV C6L gene is present in the genome of VACV
strains Western Reserve (WR) (VACV-WR_022), Copenhagen
(C6L) and MVA (MVA 019L), but absent in New York Vaccinia
Virus strain (NYVAC). C6L is presumably an immediate-early
gene based on the analysis of the C6L promoter (www.poxvirus.
org) and a genome-wide transcriptome analysis that detected C6
mRNA 30 minutes post-infection [2]. C6L encodes a 157 amino
acid protein with a predicted molecular weight of 18.2 kDa (www.
poxvirus.org). Bioinformatic analyses clustered C6L to the poxvirus
BCL-2-like gene family that includes A46R, A52R, B15R (named
B14R in WR) and K7R [3], a family of proteins that inhibit the
Toll-like receptor (TLR) signalling pathway at different levels
[4,5,6,7,8,9,10,11,12]. C6 protein is present at low levels in VACV
intracellular mature virions (IMV) [13], and binds to KRT4
(keratin 4), PDCD6IP (programmed cell death 6 interacting
protein) and TNNI2 (troponin I) [14]. Moreover, a C6 epitope
(amino acids 74–82, GFIRSLQTI in WR and SFIRSLQNI in
MVA) is highly immunogenic in BALB/c mice, and WR elicited
high levels of C6L-specific IFN-c secreting cells in mice, similarly
to VACV E3L, F2L and A52R peptides [15]. All these charac-
teristics suggest that C6 may have an important immunomodu-
latory function by antagonizing with the TLR signalling pathway.
The highly attenuated VACV strain MVA is one of the most
promising vectors to be used as an effective vaccine against HIV-1
[16]. MVA has an excellent safety profile, and MVA recombinants
expressing HIV-1 antigens induce protection after simian/human
immunodeficiency virus (SHIV) challenge, and elicit strong,
broad, polyfunctional and durable immune responses to HIV-1
antigens in different animal models and humans trials [[17,18,
19,20,21,22], for a review [23]].
We have previously constructed a recombinant MVA express-
ing codon-optimized Env as monomeric gp120 and the poly-
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that in DNA prime/MVA boost protocols in mice induced strong
immune responses to HIV-1 antigens [17,18,20]. In macaques, a
similar MVA construct expressing Env (gp120 from SHIV89.6P) and
Gag-Pol-Nef (from SIVmac239) showed strong specific CD4
+ and
CD8
+ T-cell immune responses with a bias for CD8
+, and high
protection after challenge with SHIV89.6P [22]. Furthermore, the
expression of HIV-1 antigens from MVA-B selectively induced in
humandendriticcells(DCs)theexpressionofdifferentcellulargenes
that might act as regulators of immune responses to HIV-1 antigens
[24] and MVA-B-infected DCs co-cultured with autologous T
lymphocytes induced a highly functional HIV-1-specific CD8
+ T-
cell responses including proliferation, secretion of IFN-c, IL-2,
TNF-a, MIP1b, MIP1a, RANTES and IL-6, and strong cytotoxic
activity against autologous HIV-1-infected CD4
+ T lymphocytes
[25]. Based on these previous results, MVA-B has recently entered a
phase I clinical trial in healthy volunteers in Spain. However, more
efficient poxvirus MVA-B vectors that enhance the magnitude,
breath, polyfunctionality and durability of the immune responses to
HIV-1 antigens are desirable. This is particularly relevant when a
single immunogen is desirable for mass vaccination purposes to
simplify the immunization protocols and reduce manufacturing
cost. Deletion in the vector backbone of MVA-B of known or
suggestedimmunomodulatory VACV genes, which antagonize host
specific immune responses, is a general strategy that could enhance
immunogenicity of the vector against HIV-1 antigens.
In this study, we have generated a new HIV-1 vaccine candidate,
termed MVA-B DC6L, which contains a deletion in the vector
backbone ofMVA-Bofthe VACV C6Lgene.Wehave analyzed the
expression of C6, the innate immune responses elicited by MVA-B
DC6L in human THP-1 cells and monocyte-derived DCs (moDCs)
and we have examined if the deletion of C6L gene in the candidate
HIV/AIDS vaccine vectorMVA-Bcould improve the humoral and
T-cell memory immune responses to HIV-1 antigens in mice. We
showed that C6 is expressed early during viral infection and
localizes in the cytoplasm of infected cells. MVA-B DC6L replicates
in cell culture at the same level as parental MVA-B, indicating that
C6 is not essential for virus replication. Furthermore, MVA-B
DC6Lup-regulated the expression of IFN-b and IFN-a/b-inducible
genes (IFIT1 and IFIT2) in human THP-1 cells and moDCs,
suggesting that C6 inhibits the IFN-b signalling pathway by
blocking some unknown component involved in the induction of
IFN-b. In DNAprime/MVAboost immunization protocolsin mice
comparing MVA-B DC6L and MVA-B, MVA-B DC6L signifi-
cantly enhanced the magnitude and polyfuncionality of the HIV-1-
specific CD4
+ and CD8
+ T-cell memory immune responses, which
are mostly mediated by CD8
+ T cells of effector phenotype in both
immunization groups. HIV-1-specific CD4
+ T-cell memory
responses induced by MVA-B and MVA-B DC6L were preferen-
tially Env-specific. However, while MVA-B elicited more Env- and
Gag-specific CD8
+ T-cell memory responses, MVA-B DC6L
induced preferentially Gag-Pol-Nef (GPN)-specific CD8
+ T-cell
memory responses. Moreover, MVA-B DC6L enhanced the levels
of antibodies against HIV-1 Env in comparison to MVA-B.
Altogether, our findings revealed that C6 is a new VACV
immunomodulatory protein, and that deletion of C6L in MVA
represents an attractive alternative to increase the immunogenicity
of MVA vaccine candidates.
Results
Generation and in vitro characterization of MVA-B DC6L
The function of the VACV C6L is unknown, although it is
predicted that have an immunomodulatory role [3]. To analyze
the possible immunomodulatory function of C6L, we have
constructed an MVA-B deletion mutant lacking VACV gene
C6L (MVA-B DC6L, see Materials and Methods) from the previously
described recombinant MVA-B (expressing HIV-1 Env, Gag, Pol
and Nef antigens from clade B) [18]. The diagram of the MVA-B
DC6L deletion mutant is shown in Figure 1A. PCR using primers
for the C6L locus confirmed the deletion of the C6L gene in MVA-
B DC6L (Figure 1B). Deletion of C6L from MVA-B DC6L was
also confirmed by DNA sequencing (data not shown). In addition,
analysis by Western blot confirmed that MVA-B DC6L expresses
HIV-1 antigens BX08gp120 and IIIBGPN at the same level as their
parental virus MVA-B (Figure 1C).
C6 is non-essential in cell culture
The mere isolation of MVA-B DC6L deletion mutant demon-
strated that the C6 protein is not essential for MVA replication. To
determine whether deletion of C6L altered virus multiplication, we
compared the growth of MVA-B DC6L and MVA-B in DF-1 cells.
Kinetics studies revealed that deletion ofC6L inthe MVA-Bgenome
did not affect virus replication. Hence, C6L is not essential for virus
propagationincultured cells(Figure1D).Furthermore,similartothe
parental virus MVA-B or MVA, MVA-B DC6L is an attenuated
virus which does not replicate in mammalian cells (Figure S1).
C6 is expressed early in infection
Western blot analyses using rabbit polyclonal antibodies raised
against C6 (produced as described in Material and Methods)
identified a 18.2 kDa protein in DF-1 cells infected with MVA-
B, but not with MVA-B DC6L (Figure 2A). We then determined
when C6 is expressed in DF-1 cells infected with WR and MVA
(Figure 2B). C6 expression was detected at 3 hours post-infection,
and increased with time for at least 22 hours. Treatment of DF-1
cells at the onset of infection with cytosine arabinoside (AraC), an
inhibitor of viral DNA replication and therefore late protein
expression, did not abrogate C6 expression, indicating that C6L is
an early gene. The increased amount of early C6 protein at 22 h
post-infection compared to what is produced when viral DNA
replication is inhibited by AraC (Figure 2B), is probably due to
enhanced stability of the protein after virus DNA synthesis and to
the contribution of progeny virus.
The intracellular localization of C6 was examined by immuno-
fluorescence in DF-1 cells infected with different VACV strains
(Figure 2C). C6 was detected in the cytoplasm, presumably in viral
factories, of DF-1 cells infected with WR, MVA and MVA-B, but
not in MVA-B DC6L. The reduced fluorescence intensity of C6 (in
green) indicates low levels of protein expression in comparison
with the late protein A27 (in red).
MVA-B DC6L up-regulates IFN-b expression in human
macrophages and dendritic cells
As a first step to determine whether C6 impairs the response of
innate immune cells to MVA-B, we examined by real time PCR
the expression of IFN-b, IFN-b-induced genes (IFIT1, IFIT2) and
chemokines by human THP-1 macrophages infected for 1, 3 and
6 hours with MVA, MVA-B and MVA-B DC6L (Figure 3A).
Compared to MVA and MVA-B, MVA-B DC6L (5 PFU/cell,
Figure 3A and 1 PFU/cell, data not shown) markedly up-
regulated IFN-b as well as IFIT1 and IFIT2 expression in THP-
1 cells. MVA-B DC6L also increased the expression of MIP-1a
and RANTES, but not that of IL-8 and IP-10 (Figure 3A and data
not shown).
To confirm that C6 impaired IFN-b and IFN-b-dependent gene
expression in innate immune cells, we infected human moDCs
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PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e24244Figure 1. In vitro characterization of MVA-B DC6L deletion mutant. (A) Scheme of MVA-B DC6L genome map, adapted from [72] and [73]. The
different regions are indicated by capital letters. The right and left terminal regions are shown. Below the map, the deleted or fragmented genes are
depicted as black boxes. The deleted C6L gene is indicated. The HIV-1 Gag-Pol-Nef (from isolate IIIB) and gp120 (from isolate BX08) clade B sequences
driven by the synthetic early/late (sE/L) virus promoter inserted within the TK viral locus (J2R) are indicated (adapted from [18]). (B) PCR analysis of C6L
locus. DNA extracted from DF-1 cells infected at 2 PFU/cell with MVA, MVA-B or MVA-B DC6L was used for PCR analysis. The DNA products
corresponding to the parental virus or to the deletion are indicated by an arrow on the right, with the expected size in base pairs. Molecular size
marker (1 Kb ladder) with the corresponding sizes (base pairs) is indicated on the left. Lane Mock, cells not infected. (C) Expression of HIV-1 BX08gp120
and IIIBGPN proteins in DF-1 cells infected (2 PFU/cell) with MVA-B and MVA-B DC6L, at 24 h post-infection. (D) Virus growth of MVA-B and MVA-B
DC6L in infected (0.01 PFU/cell) DF-1 cells at different times and titrated by plaque immunostaining assay with anti-WR antibodies. The mean of three
independent experiments is shown.
doi:10.1371/journal.pone.0024244.g001
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MVA-B and MVA-B DC6L and measured IFN-b, IFIT1 and
IFIT2 mRNA levels 6 h post-infection (Figure 3B). We used low
virus doses, since MVA induces apoptosis of human moDCs [26].
Similarly to the results obtained with human THP-1 cells, MVA-B
DC6L strongly increased IFN-b expression compared to MVA and
MVA-B in moDCs. Whereas the three viruses used at 0.2 PFU/ml
similarlystimulated IFIT1andIFIT2mRNAexpressioninmoDCs,
MVA-B DC6L was a much more potent inducer than MVA and
MVA-B at lower infective doses (0.002 PFU/ml, Figure 3B).
Furthermore, MVA-B DC6L stimulated the release by moDCs of
much higher levels of IFN-b (Figure 3C) and bioactive type I IFNs
than MVA and MVA-B (Figure 3D).
Thus, deletion of C6L in the MVA-B genome promotes IFN-b
production, suggesting that C6 interferes with the signalling
pathway controlling IFN-b gene expression in innate immune
cells.
MVA-B DC6L enhances the magnitude and
polyfunctionality of long-lived memory HIV-1-specific
T-cell responses
Given the immunomodulatory properties of C6, we tested
whether deletion of C6 in MVA-B DC6L could enhance its
immunogenic properties by analyzing HIV-1-specific T-cell
responses in BALB/c mice immunized with MVA-B or MVA-B
DC6L using a DNA prime (100 mg of DNA-B, i.m.)/MVA boost
(1610
7 PFU, i.p.) immunization protocol [17,18,22,27,28,29].
Animals primed with sham DNA (DNA-w) and boosted with
non-recombinant MVA were used as controls. Considering that
memory T-cell responses might be critical for protection against
HIV-1 infection [30,31,32,33], we assessed by IFN-c ELISPOT
and IFN-c and IL-2 intracellular cytokine staining (ICS) the long-
term immunogenicity profile (i.e. 53 days after the boost) elicited
by DNA-B/MVA-B and DNA-B/MVA-B DC6L vaccination in
splenocytes.
IFN-c ELISPOT revealed that, compared to MVA-B, MVA-B
DC6L enhanced 2.1-fold (p,0.005) the T-cell memory response
against HIV-1 peptide Gag-B (an HIV-1 peptide representative of
Gag antigen) (Figure 4A). Non-recombinant MVA, used as a
control, did not induce HIV-1-specific memory responses.
The phenotype of the HIV-1-specific memory T cells elicited
upon immunization with DNA-B/MVA-B and DNA-B/MVA-B
DC6L was characterized by polychromatic flow cytometry using
ICS. Splenic CD4
+ and CD8
+ T cells were co-stained for CD44
and CD62L surface markers to define the naı ¨ve (CD44
2/
CD62L
+), central memory (CM: CD44
+/CD62L
+), effector
memory (EM: CD44
+/CD62L
2) and effector memory terminally
differentiated (TEMRA: CD44
2/CD62L
2) sub-populations. We
also evaluated IFN-c and IL-2 production after in vitro stimulation
with different HIV-1 peptide pools (Env-pool, Gag-pool and GPN-
pool) that covered the entire HIV-1 sequences present in the
poxvirus vector (Figure 4B).
The overall HIV-1-specific immune response at 53 days post-
boostwasmainlymediatedbyCD8
+T cells(70%–85%)(Figure4C)
of EM and TEMRA phenotypes (Figure 4D), in both immunization
groups. However, long-term post-boost immunization with DNA-
B/MVA-B DC6L induced a higher magnitude of HIV-1-specific
CD4
+and CD8
+T-cellmemoryresponsesproducingIFN-cand/or
IL-2 than DNA-B/MVA-B [CD4
+ T cells: 1.91% in DNA-B/
MVA-B DC6L vs. 1.30% in DNA-B/MVA-B, (p,0.005); CD8
+ T
cells: 10.95% in DNA-B/MVA-B DC6L vs. 3.06% in DNA-B/
MVA-B (p,0.005)] (Figure 4C). Both vectors induced a similar
pattern of HIV-1-specific CD4
+ T-cell memory responses (with
preference towards Env) (Figure 4B and 4C). Interestingly, the
patternof CD8
+ T-cell memory responseswasdifferent between the
two vectors: DNA-B/MVA-B DC6L induced a higher percentage
of GPN-specific CD8
+ T-cell responses, while DNA-B/MVA-B
induced preferentially Env- and Gag-specific CD8
+ T-cell responses
(Figure 4B and 4C). In both immunization groups, HIV-1-specific
CD8
+ T cells were mainly of the EM (60.5–63%) and TEMRA
(37%–39.5%) phenotypes (Figure 4D). All HIV-1-specific CD4
+ T
cells were of the EM phenotype in the DNA-B/MVA-B group.
Although most of HIV-1-specific CD4
+ T cells (82.8%) were of the
EM phenotype in the DNA-B/MVA-B DC6L group, a substantial
proportion (17.2%) of cells expressed the TEMRA phenotype
(Figure 4D). No CM T cells producing IFN-c and/or IL-2 were
detected in both immunization groups (Figure 4D).
Figure 2. Characterization of C6 expression and localization. DF-1 cells were infected with 5 PFU/cell of MVA-B and MVA-B DC6L (A) or WR
and MVA (B) in the presence or absence of AraC (B). Cells extracts collected 24 hours post-infection (A) or at the indicated time (B) were analyzed by
SDS-PAGE. VACV C6 protein was detected by Western blot using rabbit polyclonal sera against C6. (C) DF-1 cells were infected with WR, MVA, MVA-B
or MVA-B DC6L or mock-infected for 18 hours. The localization of C6 was analyzed by immunofluorescence, as described in Materials and Methods.
Cells were staining with DAPI (blue, staining cellular nucleus), purified rabbit polyclonal anti-C6 (green) and anti-14K (red).
doi:10.1371/journal.pone.0024244.g002
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responses, we next evaluated the production of IFN-c and/or IL-2
by HIV-1-specific CD4
+ and CD8
+ T-cell memory cells (Figure 5).
DNA-B/MVA-B DC6L increased the polyfunctionality of HIV-1-
specific CD4
+ and CD8
+ T memory cells consisting of cells
producing both IFN-c and IL-2 [CD4
+ T cells: 34% in DNA-B/
MVA-B DC6L vs. 16% in DNA-B/MVA-B, (p,0.005); CD8
+ T
cells: 29% in DNA-B/MVA-B DC6L vs. 16% in DNA-B/MVA-B,
(p,0.005)] (Figure 5).
Altogether, these findings established that immunization with
DNA-B/MVA-B DC6L significantly increased the magnitude and
polyfunctionality of HIV-1-specific CD4
+ and CD8
+ T-cell
memory responses, with most of the response mediated by EM
and TEMRA T cells. HIV-1-specific CD4
+ T-cell memory
responses were preferentially Env-specific following DNA-B/
MVA-B and DNA-B/MVA-B DC6L vaccination. Yet, DNA-B/
MVA-B DC6L induced an immunodominance towards CD8
+
GPN-specific T-cell memory responses, while DNA-B/MVA-B
induced preferentially CD8
+ Env- and Gag-specific T-cell memory
responses.
MVA-B DC6L enhances the levels of antibodies against
HIV-1 gp120
Since cells infected with MVA-B release monomeric gp120 [18],
we evaluated whether DNA-B/MVA-B and DNA-B/MVA-B
DC6L immunization stimulated the production of antibodies
against HIV-1 Env. Anti-gp120 antibodies in serum from
individual mouse collected 53 days post-boost were quantified by
ELISA, measuring the levels of specific antibodies reactive against
gp160 protein from the HIV-1 clone LAV (clade B). Compared to
DNA-B/MVA-B, DNA-B/MVA-B DC6L immunization in-
creased 44-fold the levels of antibodies reactive against gp160
protein (Figure 6). Therefore, MVA-B DC6L increases the
humoral immune responses against HIV-1 Env.
Discussion
The MVA vector, despite of its attenuated phenotype, still
contains genes that encode proteins that can interfere with host
immune responses to viral infection [34], and it is described that
deletion of immunomodulatory proteins in orthopoxviruses can
enhance immune responses ([17,34,35,36,37,38,39]). The function
of some of these genes, like the VACV gene C6L, is unknown. We
report here the immunomodulatory role of C6L, showing the
effects of the C6 protein on virus replication, innate immune
sensing and immunogenicity in vivo.
MVA-B, the attenuated VACV vector MVA expressing the
clade B HIV-1 antigens Env, as monomeric gp120, and Gag, Pol
and Nef, as a polyprotein of about 160 kDa is considered a vaccine
candidate against HIV/AIDS [18] based on preclinical studies in
different animal models [17,18,20,22] and on gene signatures
triggered in human DCs infected with MVA-B, where the
expression of HIV-1 proteins induced the expression of immuno-
modulatory molecules such as cytokines, cytokine receptors,
chemokines, chemokine receptors and molecules involved in
antigen uptake and processing [24]. Moreover, human DCs
exposed to MVA-B induced highly functional HIV-1-specific
CD8
+ T-cell responses in HIV-1 infected individuals [25]. Thus,
due to the good immunogenicity behavior of MVA-B, a
prophylactic phase I clinical trial was initiated in Spain.
To improve the immunogenicity elicited by MVA-B and to
investigate the possible immunomodulatory role of C6L we have
removed from the MVA-B viral genome the C6L gene, generating
the deletion mutant termed MVA-B DC6L. First, we showed in
cultured cells that MVA-B DC6L does not express the C6 protein,
but efficiently produced the four HIV-1 antigens (Env, Gag, Pol
and Nef) in a stable manner and at the same level as MVA-B
during the course of virus infection. Also, MVA-B DC6L replicates
similarly to MVA-B in cultured cells, indicating that deletion of
C6L has no effect on virus propagation. Therefore, C6L is not
essential for viral replication in cell culture. Moreover, similar to
MVA-B, MVA-B DC6L maintains an attenuated phenotype and
does not replicate in mammalian cells. Western blot analyses
demonstrated that C6 is expressed early in cells infected with the
VACV strains WR and MVA. This early expression profile is
consistent with genome-wide transcriptome analyses that detected
C6 mRNA 30 minutes post-infection [2]. Most VACV immuno-
modulatory proteins are expressed early during infection, and the
early expression pattern of C6 suggests that it is involved in
immune evasion as we confirmed in experiments using human
macrophages and DCs. In addition, C6 localizes to the cytoplasm
of infected cells, opening the possibility that C6 modulates, directly
or indirectly, intracellular signalling pathways controlling immune
responses.
Yeast two-hybrid and pull-down assays revealed that VACV C6
protein binds to three host human cell proteins [14]. However,
none of these proteins seems to be directly related with the host
immune response. One of the C6 binding partners is programmed
cell death 6 interacting protein (PDCD6IP/ALIX), which has
been involved in the regulation of apoptosis, cytokinesis and HIV-
1 budding. VACV C6 also interacts with keratin 4 (KRT4),
present in intermediate filaments, and which also binds IMV
surface protein A27. C6 protein has also been detected in a low
proportion in intracellular mature virions [13], similar to other
proteins of the poxvirus family Pox_A46 (A46). One possible
reason for presence of C6 in the virion could be that C6 is
necessary for viral cycle early after virus entry or that C6 have a
function in IMV-cell attachment, fusion, and/or microtubule
transport through their interaction with KRT4. Finally, C6 also
binds to troponin I, skeletal, fast (TNNI2), a co-activator of
estrogen receptor-related receptor a (ERRa), suggesting that C6
could have a role in ERRa-mediated transcriptional activity.
Additional experiments will be required to decipher the relation-
ship between the C6 interaction with binding partners and C6
immunomodulatory function.
A bioinformatic analysis indicated that C6L has sequence
similarities with the poxvirus family Pox_A46, a poxvirus Bcl-2-
like gene family, which includes A46R, A52R, K7R and B15R
Figure 3. MVA-B DC6L induces the production of IFN-b and type I IFN inducible genes in macrophages and dendritic cells. Human
THP-1 macrophages (A) and moDCs (B, C, D) were infected with MVA, MVA-B and MVA-B DC6L (5 PFU/cell in A, and 0.2, 0.02 and 0.002 PFU/cell in B,
C and D). At different time post-infection (1 h, 3 h and 6 h in A, 6 h in B), RNA was extracted and the mRNA levels of IFN-b, type I IFN inducible genes
(IFIT1 and IFIT2), chemokines and HPRT were analyzed by RT-PCR. Results were expressed as the ratio of gene to HPRT mRNA levels. A.U: arbitrary
units. Data are means 6 SD of duplicate samples. * p,0.05, ** p,0.005. (C, D) Human moDCs were infected with 0.2, 0.02 and 0.002 PFU/cell of MVA,
MVA-B and MVA-B DC6L. Six hours later, cell-free supernatants were collected to quantify the concentration of IFN-b by ELISA (C) and the
concentration of type I IFN using the HL116 reporter cell line (D). Results were expressed in absorbance values at 450 nm (C), and in luciferase units
(D). Data are means 6 SD of duplicates and are representative of two independent experiments. * p,0.05.
doi:10.1371/journal.pone.0024244.g003
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K7 [9,10,11] and B15 [5,6] are intracellular proteins expressed by
VACV that inhibit TLR signalling at different levels. A46 contains
a Toll/IL-1 receptor (TIR) domain and targets several TIR
adaptor proteins (MyD88, TIRAP, TRIF and TRAM) [4,12],
blocking MAP kinase activation and TRIF-mediated IRF3
activation. A52 and K7 targets IRAK2 and TRAF6 inhibiting
TLR-dependent NF-kB activation [11]. K7 also interacts with
DDX3, which is part of the complex that activates transcription
factor IRF3, thus inhibiting IRF3 mediated IFN-b gene
transcription [9,10]. B15 inhibits IKKb phosphorylation thereby
impairing NF-kB activation [5,6]. Considering the sequence
similarities of C6 with A46, A52, K7 and B15, we speculate that
C6 may interfere with host immune responses through inhibition
of TLR signalling pathways.
To examine the immunomodulatory role of C6L, we charac-
terized the profile of the innate immune sensing induced by MVA-
B DC6L, MVA-B and MVA in human macrophages and moDCs.
MVA-B DC6L significantly up-regulated IFN-b and IFN-a/b-
inducible genes (IFIT1 and IFIT2) mRNA levels and increased
IFN-b secretion, suggesting that C6 blocks some component of the
IFN-b signalling pathway. The effect was mainly observed 6 hours
Figure 4. Immunization with MVA-B DC6L enhances the magnitude of HIV-1-specific CD4
+ and CD8
+ T-cell memory immune
responses. Splenocytes were collected from mice (n=4 per group) immunized with DNA-B/MVA-B, DNA-B/MVA-B DC6L or DNA-w/MVA, 53 days
after the last immunization. (A) Gag-B-specific IFN-c secreting splenocytes were quantified by ELISPOT assay. Data are means 6 SD of triplicate
cultures. ** p,0.005. (B–D) Flow cytometry phenotypic analysis of Env, Gag and GPN HIV-1 specific CD4
+ and CD8
+ T-cells. CD44 and CD62L
expression was used to identify central memory (CM: CD44
+/CD62L
+), effector memory (EM: CD44
+/CD62L
2) and effector memory terminally
differentiated (TEMRA: CD44
2/CD62L
2) sub-populations. IFN-y and IL-2 production was analyzed by ICS. (B) A representative flow cytometry is
shown. The T-cell memory sub-populations are depicted as density plots. Blue and green dots represent T-cells producing IFN-y and IL-2, respectively.
(C) Percentage of splenic Env, Gag and GPN HIV-1-specific CD4
+ and CD8
+ memory T-cells. Frequencies were calculated by reporting the number of
memory T-cells producing IFN-c and/or IL-2 to the total number of CD4
+ and CD8
+ splenocytes. Values from unstimulated controls were subtracted in
all cases. ** p,0.005. (D) Pie charts representing the proportion of CM, EM and TEMRA within the Env, Gag and GPN HIV-1-specific CD4
+ and CD8
+
memory T-cells. (A–D) Data are from one experiment representative of two experiments.
doi:10.1371/journal.pone.0024244.g004
Figure 5. Immunization with MVA-B DC6L enhances the polyfunctionality of HIV-1-specific CD4
+ and CD8
+ T-cell memory immune
responses. Splenocytes were collected from mice (n=4 per group) immunized with DNA-B/MVA-B, DNA-B/MVA-B DC6L or DNA-w/MVA, 53 days
after the last immunization and analyzed by flow cytometry as described in Figure 4. The polyfunctionality of Env+Gag+GPN HIV-1-specific CD4
+
(left part) and CD8
+ (right part) memory T cells was defined based on IFN-c and/or IL-2 production. All the possible combinations of the responses
are shown on the X axis. The percentages of IFN-c and/or IL-2 producing memory T-cells among total CD4
+ and CD8
+ T cells are shown on the Y axis.
** p,0.005. The pie charts summarize the data. Each slice corresponds to the proportion of CD4
+ or CD8
+ T cells producing single (IFN+ or IL-2+)o r
double (IFN+/IL-2+) responses within the total HIV-1-specific CD4
+ or CD8
+ T-cell memory populations. The size of the pie chart represents the
magnitude of the specific HIV-1 memory immune response induced.
doi:10.1371/journal.pone.0024244.g005
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viral exposure and high viral doses induce extensive apoptosis
[26]. Previous experiments revealed in macrophages infected with
MVA a critical role for TLR2-TLR6-MyD88 in the production of
IFN-b-independent chemokines and of MDA-5-IPS-1 in the
production of IFN-b-dependent chemokines [40]. Phosphorylation
of IRF3, IRF7 and STAT-1, which are essential for the
transcription of the IFN-b gene (IRF3) and critical targets of the
IFN-b signalling pathway required for the transcriptional
activation of IFN-b-dependent genes (IRF7 and STAT-1), were
detected in THP-1 cells infected with MVA and associated with
the induction of IFN-b [40]. Whether C6 blocks directly or
indirectly IRF3, IRF7 or STAT-1 expression or activation by
phosphorylation is under investigation.
Since our goal is to develop modified MVA-B with enhanced
immunogenicity to HIV-1 antigens, we carried out a detail
characterization of the HIV-1-specific memory immune responses
induced in mice using DNA prime/MVA boost approach, and
compared parental MVA-B with the deletion mutant MVA-B
DC6L. We used ICS, which allows a more extensive character-
ization of T-cell effector functions at the single-cell level [41]. Our
findings revealed that at 53 days post-boost, DNA-B/MVA-B
DC6L triggered higher magnitude and polyfunctionality of total
HIV-1-specific CD4
+ and CD8
+ T-cell memory immune respons-
es (specific for Env, Gag and GPN) than DNA-B/MVA-B. The
vaccine-induced T-cell memory responses were predominantly
mediated by CD8
+ T cells in both immunization groups, with
most of the response mediated by CD8
+ EM and TEMRA T cells,
which have been described to have a powerful and direct antiviral
capacity [30,31,32,33] and have been associated with HIV-1 viral
control in early and chronic infection [42,43,44]. HIV-1-specific
CD4
+ T-cell memory responses were preferentially Env-specific in
both immunization groups, similar to what it is obtained with
other MVA HIV-1 vaccines as MVA-CMDR [45] or other
NYVAC HIV-1 vaccines [21,46,47]. Furthermore, immunization
with DNA-B/MVA-B DC6L induced preferentially GPN-specific
CD8
+ T-cell memory responses compared with DNA-B/MVA-B.
The shift towards GPN-response triggered by MVA-B DC6L
might result from the activation of the intrinsic pathway of antigen
presentation by the Gag-Pol-Nef intracellular polyprotein due to
the increased IFN-b production promoted by the deletion of C6L.
However, it is not clear yet whether the enhanced CD8
+ T-cell
response to GPN is due to a greater breadth of response or could
reflect an enhanced response to single epitopes. The functional
relevance of Env-specific CD4
+ T-cell responses or GPN-specific
CD8
+ T-cell responses in setting of vaccination for prevention of
HIV-1 infection needs to be further explored. Further experiments
need to be done in other animal models such as non-human
primates to determine the possible benefits of the response elicited
by MVA-B DC6L. Interestingly, enhanced Gag response has been
associated with better control of virus in macaques infected with
SIV and in HIV-1-infected individuals [48,49].
How significant are our in vivo findings with regard to immune
requirements for HIV-1 protection? While definition of correlates
of protection to HIV-1 remains to be firmly established, there are
a number of markers that can be used as potential indicators for an
effective HIV-1 vaccine, such as: 1) activation of HIV-1-specific
CD4
+ and CD8
+ T cells; 2) triggering polyfunctional responses; 3)
enhanced magnitude and breath of the immune response; 4)
induction of long-term memory cells of effector phenotype; 5)
production of neutralizing antibodies with broad specificities.
Several features of the T-cell response to HIV-1 are correlated
with control of viral replication [50,51], and a correlation of the
CD8
+ T-cell response with a lowering of peak viremia in acute
HIV-1 infection has been described [52,53]. Also, in non-human
primates there is a good correlation between vaccine-induced
HIV-1-specific cellular immunogenicity and protection after a
challenge with a pathogenic SHIV [22,27,28], where CD8
+ T cells
play an important role in immunity to HIV-1 [54]. Several studies
have demonstrated that T-cell polyfunctionality is associated with
protective antiviral immunity [[50,51,55,56,57], for a review [33]].
In HIV-1-infected patients that are nonprogressors, HIV-1-
specific CD8
+ T cells were polyfunctional [50]. Furthermore, the
generation of memory CD8
+ T cells of EM and TEMRA phe-
notypes have been associated with the control of HIV-1 infection
in patients [42,43,44] and in non-human primates [58]. Moreover,
it was described recently that effector memory T-cell responses
elicited after vaccination in non-human primates could control
highly pathogenic SIVmac239 infection early after mucosal chal-
lenge, showing the important role of memory T-cell responses
[59]. These observations suggest that polyfunctional CD8
+ T cells
and effector memory T cells are important components of a
protective immune response [33]. Importantly, both MVA-B and
MVA-B DC6L triggered immune responses that fulfill several of
the characteristics of a promising candidate HIV-1 vaccine.
Indeed immunization with DNA-B/MVA-B DC6L induced
activation of HIV-1-specific CD4
+ and CD8
+ T cells, enhanced
magnitude and polyfunctionality of the immune response,
triggered long-term memory T cells of effector phenotype, and
increased the levels of antibodies directed against Env.
However, the immunological parameters required for protec-
tion against HIV-1 infection in humans remain unknown. The
phase III Thai clinical trial reported a modest protection of about
31% against HIV-1 infection in vaccinees with the combination of
recombinant vaccines canarypox and gp120, in spite of poor
neutralizing antibodies and of reduced T-cell responses against
HIV-1 [60]. The phase III Thai trial has pointed out that further
developments of poxvirus vectors is needed. Among MVA vectors,
Figure 6. Immunization with MVA-B DC6L enhances the
humoral immune responses elicited against HIV-1 gp160
protein. Serum was collected from individual mouse immunized with
DNA-B/MVA-B, DNA-B/MVA-B DC6L or DNA-w/MVA (n=4 in DNA-B/
MVA-B and DNA-w/MVA; n=3 in DNA-B/MVA-B DC6L), 53 days after the
last immunization. Anti-gp120 antibody titers were determined by
ELISA as described in Materials and Methods. Titers represent the last
dilution of the serum that signals 3-fold higher than signals obtained
with the serum of naı ¨ve mice. The dotted line represents the limit of
detection of the ELISA. The horizontal bar represents the mean value.
Each dot represents one mouse. * p,0.05.
doi:10.1371/journal.pone.0024244.g006
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performed with DNA prime/MVA boost protocols or with
MVA administered alone [61,62,63,64,65] and revealed promis-
ing findings. These studies proved the safety and immunogenicity
of the MVA vectors and reported an important proportion of
responders with multigenic responses that persisted up to one year
post-vaccination. In light of our results, one might postulate that
MVA-B with deletion of the C6L gene could improve the
immunogenicity of the vaccines by enhancing the magnitude,
polyfunctional and memory responses T cell responses.
In conclusion, we show that deletion of C6L on MVA-B up-
regulates IFN-b expression in human macrophages and DCs, and
improves MVA-B immunogenicity in vivo, increasing the magni-
tude, polyfunctionality and memory T-cell responses against HIV-
1 and the generation of Env-specific antibodies. Thus, VACV C6
protein interferes with host immune responses by at least in part,
blocking some component(s) of the IFN-b signalling pathway.
Understanding the mechanism of action of C6 will provide new
insights in virus-host cell interactions and viral immunomodula-
tion. Further work should be devoted to explore the relevance of
our findings in a non-human primate model, as MVA-B DC6L
represents a promising vector for developing HIV-1 vaccines.
Materials and Methods
Ethics Statement
The animal studies were approved by the Ethical Committee of
Animal Experimentation (CEEA-CNB) of Centro Nacional de
Biotecnologia (CNB-CSIC, Madrid, Spain) in accordance with
national and international guidelines and with the Royal Decree
(RD 1201/2005). Permit numbers: 152/07 and 080030.
Studies with peripheral blood mononuclear cells (PBMCs) from
healthy blood donors recruited by the Blood Center of Lausanne
(Switzerland) were approved by the ethics commission for clinical
research from the Faculty of Biology and Medicine of Lausanne.
Written informed consent was obtained from donors. All infor-
mation were kept confidential by the Blood Center.
Cells and viruses
Primary chicken embryo fibroblast cells (CEF) [18] and DF-1
cells (a spontaneously immortalized chicken embryo fibroblast cell
line. ATCC, Manassas, VA) were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum
(FCS). The human monocytic THP-1 cell line (ATCC, Manassas,
VA) was cultured in complete RPMI 1640 medium containing
2 mM L-glutamine, 50 mM 2-mercaptoethanol, 100 IU/ml pen-
icillin, 100 mg/ml streptomycin (all from Invitrogen, San Diego,
CA) and 10% heat-inactivated FCS (Sigma-Aldrich, St. Louis,
MO), as previously described [40]. THP-1 cells were differentiated
into macrophages by treatment with 0.5 mM phorbol 12-
myristate 13-acetate (PMA, Sigma-Aldrich) for 24 h before usage.
Adult peripheral blood mononuclear cells (PBMCs) from healthy
donors (recruited by the Blood Center, Lausanne, Switzerland)
were seeded in 6-well tissue culture plates (3610
6 cells/well) in
complete RPMI medium supplemented with 10% heat-inactivated
FCS and incubated at 37uC for 3 h. Non-adherent cells were
removed and medium replaced by fresh complete RPMI medium
containing 50 ng/ml granulocyte-macrophage colony-stimulating
factor (GM-CSF) and 20 ng/ml IL-4 (R&D Systems, Minneapolis,
MN). moDCs were collected after 7 days of incubation. Cell
cultures were performed at 37uC (CEF, THP-1 cells and moDCs)
or 39uC (DF-1) in a humidified incubator containing 5% CO2.
The poxvirus strains used in this work included: Western
Reserve (WR), modified vaccinia virus Ankara (MVA) and the
recombinant MVA-B expressing the HIV-1BX08 gp120 and HIV-
1IIIB Gag-Pol-Nef proteins [18]. Viruses were grown in CEF cells,
purified through two 36% (w/v) sucrose cushions, and titrated by
plaque immunostaining assay [66]. Cell lines were infected with
viruses as previously described [18,40].
Construction of plasmid transfer vector pGem-RG-C6L
wm
The plasmid transfer vector pGem-RG-C6L wm was used for
the construction of the recombinant virus MVA-B DC6L, with
C6L (C6L in Copenhagen strain of VACV is equivalent to MVA
019L in MVA) gene deleted (for simplicity, we used throughout the
work the ORF nomenclature of Copenhagen strain to refer the
MVA genes). pGem-RG-C6L wm was obtained by sequential
cloning of five DNA fragments containing dsRed2 and rsGFP
genes and C6L recombination flanking sequences into the plasmid
pGem-7Zf(2) (Promega). The construction of the plasmid pGem-
Red-GFP wm (4540 bp), containing dsRed2 and rsGFP genes
under the control of the synthetic early/late (E/L) promoter was
previously described [17]. MVA-B genome was used as the
template to amplify the right flank of C6L gene (391 bp) with
oligonucleotides RFC6L-AatII-F (59-CTCGTCGACGTCCGAC-
CAATCTGGGC-39) (AatII site underlined) and RFC6L-XbaI-R
(59-TTCCTATCTAGATTTCTCTGTTTAAA-39) (XbaI site
underlined). This right flank was digested with AatII and XbaI
and cloned into plasmid pGem-Red-GFP wm previously digested
with the same restriction enzymes to generate pGem-RG-RFsC6L
wm (4898 bp). The repeated right flank of C6L gene (391 bp) was
amplified by PCR from MVA-B genome with oligonucleotides
RF9C6L-XmaI-F (59-CTCGTCCCCGGGCGACCAATCTGG-
GC-39) (XmaI site underlined) and RF9C6L-ClaI-R (59-TT-
CCTAATCGATTTTCTCTGTTTAAA-39) (ClaI site under-
lined), digested with XmaI and ClaI and inserted into the
XmaI/ClaI-digested pGem-RG-RFsC6L wm to generate pGem-
RG-RFdC6L wm (5259 bp). The left flank of C6L gene (413 bp)
was amplified by PCR from MVA-B genome with oligonucleotides
LFC6L-ClaI-F (59-ATACGCATCGATGATAAACTTAATGA-
39) (ClaI site underlined) and LFC6L-BamHI-R (59-GTTG-
TTGGATCCATTGGTAGATGACG-39) (BamHI site under-
lined), digested with ClaI and BamHI and inserted into the
ClaI/Bam HI-digested pGem-RG-RFdC6L wm. The resulting
plasmid pGem-RG-C6L wm (5642 bp) was confirmed by DNA
sequence analysis and directs the deletion of C6L gene from MVA-
B genome.
Construction of MVA-B DC6L deletion mutant
MVA-B DC6L deletion mutant was constructed by screening
for transient Red2/GFP co-expression using dsRed2 and rsGFP
genes as the transiently selectable markers, as previously described
[17]. Briefly, 3610
6 DF-1 cells were infected with MVA-B at a
multiplicity of 0.05 PFU/cell and then transfected 1 h later with
6 mg of DNA from plasmid pGem-RG-C6L wm using Lipofecta-
mine (Invitrogen) according to the manufacturer’s recommenda-
tions. After 72 hours, the cells were harvested, lysed by freeze-
thaw cycling and sonicated. Following 6 consecutive rounds of
plaque purification in DF-1 cells, MVA-B DC6L was obtained and
the deletion of C6L gene was confirmed by PCR amplifying the
C6L locus. MVA-B DC6L was grown in CEF cells, purified by
centrifugation through two 36% (w/v) sucrose cushions in 10 mM
Tris-HCl pH 9, and titrated in DF-1 cells by plaque immuno-
staining assay, using rabbit polyclonal antibody against VACV
strain WR (Centro Nacional de Biotecnologı ´a; 1:1000) followed by
anti-rabbit-HRP (Sigma; 1:1000), as previously described [66].
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mycoplasma or bacteria.
PCR analysis of MVA-B DC6L deletion mutant
To test the purity of MVA-B DC6L deletion mutant, viral DNA
was extracted from DF-1 cells mock-infected or infected at
2 PFU/cell with MVA, MVA-B or MVA-B DC6L. Primers
RFC6L-AatII-F and LFC6L-BamHI-R (described above) span-
ning C6L flanking regions were used for PCR analysis of C6L
locus. The amplification protocol was previously described [17].
PCR products were resolved in 1% agarose gel and visualized by
ethidium bromide staining. The C6L deletion was also confirmed
by DNA sequence analysis.
Expression of HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef
proteins by MVA-B DC6L deletion mutant
To test the correct expression of HIV-1 proteins HIV-1BX08
gp120 and HIV-1IIIB Gag-Pol-Nef (GPN), monolayers of DF-1
cells were mock-infected or infected at 2 PFU/cell with MVA,
MVA-B or MVA-B DC6L. After 24 hours, cells were lysed in
Laemmli buffer, cells extracts were fractionated in 12% SDS-
PAGE and analyzed by Western blot using rabbit polyclonal anti-
gp120 antibody against IIIB (Centro Nacional de Biotecnologı ´a;
1:3000) or polyclonal anti-gag p24 serum (ARP 432, NIBSC,
Centralised Facility for AIDS reagent, UK; 1:3000) followed by
anti-rabbit-HRP (Sigma; 1:5000) to evaluate the expression of
gp120 and GPN proteins, respectively.
Analysis of virus growth
To determine virus-growth profiles, monolayers of DF-1 cells
grown in 12-well tissue culture plates were infected in duplicate at
0.01 PFU/cell with MVA-B or MVA-B DC6L. Following virus
adsorption for 60 min at 37uC, the inoculum was removed. The
infected cells were washed once with DMEM without serum and
incubated with fresh DMEM containing 2% FCS at 37uCi na5 %
CO2 atmosphere. At different times post-infection (0, 24, 48 and
72 hours), cells were collected, freeze-thawed three times and
briefly sonicated. The intracellular viruses were titrated by
immunostaining as described above.
Expression of C6 protein in E. coli and production of anti-
C6 polyclonal antibodies
The C6 ORF (MVA 019L, 157 aa, 18.2 kDa) was amplified by
PCR using primers C6L-NheI-F (59-AGGCTAGCGTTTAGG-
AAAAAAAAATATC-39) (NheI site underlined) and C6L-BamHI-R
(59-AAGGATCCCATGAATGCGTATAATA-39) (BamHI site under-
lined), and VACV MVA DNA as template. The product (488 bp)
was digested with NheI and BamHI and cloned into plasmid pET-
27b(+) (Novagen). The ligation product was used to transform BL21
E.coli, and the plasmid of a kanamycin-resistant positive colony was
sequenced to confirm that it contained the C6L sequence. The
plasmid generated was termed pET-27b-C6L (5837 bp). Plasmid
pET-27b(+) provided a tract of 6 histidines at the carboxyl terminus
of the C6 protein, generating a recombinant C6 protein of about
24 kDa. Kanamycin-resistant colonies were grown in Luria broth
medium until an OD of 0.5 at 595 nm. Isopropyl 1-thio-b-D-
galactopyranoside was added (0.5 mM) and the culture grown for 4
additional hours. Cells were pelleted by centrifugation. For lysis,
cells were suspended in 50 mM Tris–HCl, pH 7.5, 0.3 M NaCl,
8 M Urea, and incubated with 1 mg/ml lysozyme for 30 min in the
presence of 1 mM phenylmethylsulfonyl fluoride. The suspension
was freezed-thawed twice. Cellular debris was removed by
centrifugation, and the supernatant was incubated with Probound
resin (Invitrogen). Elution was carried out with different concen-
trations of imidazol (100 to 500 mM) in 50 mM Tris–HCl, pH 7.5,
0.3 M NaCl. Eluted fractions were pooled and loaded on desalting
columns following the manufacturer’s protocol (GE-Healthcare,
Freiburg, Germany), and fractions were collected. Protein was
quantified using the Bradford assay, fractionated by 12% SDS-
PAGE and analyzed by Western blot using anti-His tag antibody
(1:5000) to detect the presence of VACV C6 protein. Fractions
containing the C6 protein (with an estimated purity of 90%) were
stored in aliquots at 220uC. The C6 protein (1150 mg) was injected
into New Zealand White rabbits to produce anti-C6 serum and
rabbit polyclonal antibody against C6 (Biomedal Laboratories,
Sevilla, Spain).
Early expression of C6 protein in cells infected by WR and
MVA
DF-1 cells were infected with WR and MVA at 5 PFU/cell in
the presence or absence of 40 mg/ml of cytosine arabinoside
(AraC; an inhibitor of viral DNA replication and therefore late
protein expression). At different times post-infection (30 min, 3 h,
6 h and 22 h) cells were lysed in Laemmli buffer, cells extracts
fractionated by 12% SDS-PAGE and analyzed by Western blot
using rabbit polyclonal sera anti-C6 (Biomedal; 1:100), followed by
anti-rabbit-HRP (Sigma; 1:5000). Expression of C6 protein was
analyzed also 22 h post-infection in DF-1 cells infected at 5 PFU/
cell with MVA-B and MVA-B DC6L.
Immunofluorescence
DF-1 cells were grown on glass coverslips (borosilicate glass;
BDH) in 12-well plates and infected at 0.5 PFU/cell with WR,
MVA, MVA-B or MVA-B DC6L. At 18 h post-infection cells
were washed three times in ice-cold PBS, fixed in 4% para-
formaldehyde, permeabilized with 0.1% Triton X-100 (Sigma),
and blocked with 10% FCS. Cells were incubated with antibodies
to the VACV C6 viral protein (rabbit polyclonal anti-C6, 1:500),
and A27L viral protein (mouse monoclonal antibody C3anti-14K,
1:400), together with the DNA-staining reagent DAPI (1:200) at
RT for 1 h. Samples were incubated with the secondary antibodies
(Alexa-488 Goat anti-rabbit IgG and Alexa-546 Goat anti-mouse
IgG; 1:500) at RT for 1 h, washed and mounted in ProLong
TM
Antifade Kit medium. Images were obtained with a Bio-Rad
Radiance 2100 confocal laser microscope.
RNA analysis by quantitative real-time polymerase chain
reaction
Total RNA was isolated from THP-1 cells and moDCs infected
with MVA, MVA-B and MVA-B DC6L, using the RNeasy kit
(Qiagen, Hombrechtikon, Switzerland). Reverse transcription of
100 ng to 500 ng of RNA was performed using the ImProm II RT
System kit (Promega). Quantitative PCR was performed with a
7500 Fast Real-Time PCR System (Applied Biosystems, Rotkreuz,
Switzerland) using the Power SYBR Green PCR Master Mix
(Applied Biosystems), as previously described [40]. Expression
levels of IFN-b, IFIT1, IFIT2, RANTES, MIP-1a, IL-8, IP-10 and
HPRT genes were analyzed by real-time PCR using specific oligo-
nucleotides (sequence be provided upon request). Gene specific
expression was expressed relative to the expression of HPRT in
arbitrary units (A.U.). All samples were tested in duplicates.
IFN-b and type I IFN measurement
IFN-b concentrations in cell-culture supernatants were mea-
sured by ELISA (PBL Biomedical Laboratories, Picataway, NJ).
Type I IFNs were quantified as previously described using the
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under the control of the IFN-a/b-inducible 6–16 promoter
[67,68,69]. HL116 cells were grown in DMEM supplemented
with 10% FCS and 50 mM hypoxanthine-aminopterin-thymidine.
HL116 cells (10
5 cells in a 96-well plate) were incubated for 6 h
with cell culture supernatants or recombinant human IFN-b (Cell
Sciences, Canton, MA) as a standard. Luciferase activity in HL116
lysates was quantified using the Luciferase assay reagent (Promega)
and a luminometer (EG&E Berthold, Germany).
Peptides
HIV-1 peptide pools were provided by the EuroVacc Founda-
tion. They spanned the entire Env, Gag, Pol and Nef regions from
clade B HIV-1 as consecutive 15-mers overlapped by 11 amino
acids.The HIV-1BX08 gp120 protein wasspanned by the Env-1 and
Env-2 pools. The HIV-1IIIB Gag-Pol-Nef fusion protein was
spanned by the following pools: Gag-1, Gag-2, GPN-1, GPN-2,
GPN-3 and GPN-4. The size and number of peptides included in
each pool was previously described [17]. For immunological
analysis we grouped the peptides in three main pools: Env, Gag
and GPN. The Env-pool comprises Env-1+Env-2; Gag-pool
comprises Gag-1+Gag-2; and GPN-pool comprises GPN-1+GPN-
2+GPN-3+GPN-4. HIV-1 peptide Gag-B (AMQMLKETI), from
clade B, was produced at Centro Nacional de Biotecnologı ´a.
Mice immunization schedule
BALB/c mice (6–8 weeks old) were purchased from Harlan. A
DNA prime/MVA boost immunization protocol was performed as
previously described [17,18]. Groups of animals (n=4) received
100 mgo fD N A - B( 5 0mgo fp C M V - BX08gp120+50 mg of pCDNA-
IIIBGPN) by intramuscular route (i.m.) and two weeks later received
an intraperitoneal (i.p.) inoculation of 1610
7 PFU of the corre-
sponding recombinant vaccinia viruses (MVA-B or MVA-B DC6L)
in 200 ml of PBS. Mice immunized with sham DNA (DNA-w)
followed by MVA booster were used as control group. At 53 days
after the last immunization, mice were sacrificed and spleens
processed for IFN-c ELISPOT and intracellular cytokine staining
(ICS) assays. Two independent experiments have been performed.
IFN-c ELISPOT assay
IFN-c ELISPOT assay was performed as previously described
[17,70].
Intracellular Cytokine Staining assay (ICS)
The phenotypes of responding T memory cells were analyzed
by ICS and fluorescence-activated cell sorting analysis as described
elsewhere [22]. After an overnight rest, 5610
6 splenocytes
(depleted of red blood cells) were resuspended in RPMI 1640
supplemented with 10% FCS and containing 1 ml/ml Golgiplug
(BD Biosciences) to inhibit cytokine secretion. Cells were seeded
on M96 plates and stimulated with Env-, Gag- or GPN-pools of
peptides (5 mg/ml). After 6 h of stimulation, cells were washed,
stained with anti-CD4-Alexa 700, -CD8-FITC, -CD44-PECy5
and -CD62L-PE antibodies, fixed, permeabilized using the BD
Cytofix/Cytoperm
TM Kit (Becton Dickinson) and stained with
anti-FN-c-PECY-7 and anti-IL-2-Alexa-647 antibodies (all anti-
bodies were from BD Biosciences). Dead cells were excluded using
the violet LIVE/DEAD stain kit (Invitrogen). Acquisition and
analyses were performed using a LSRII flow cytometer (Becton
Dickinson) and FlowJo version 8.5.3 (Tree Star, Ashland, OR).
The production of IFN-c and IL-2 was analyzed in each of the T-
cell memory populations: central memory (CM: CD44
+/CD62L
+),
effector memory (EM: CD44
+/CD62L
2) and effector memory
terminally differentiated (TEMRA: CD44
2/CD62L
2) sub-popu-
lations.
Antibody measurements by ELISA
Antibodies anti-HIV-1 gp160LAV envelope protein were
measured by ELISA as previously described [17,18].
Statistical procedures
The statistical analysis of ELISPOT and ICS assays was realized
as previously described [17,71]. We have developed a novel
approach that corrects measurements for the medium response
(RPMI), calculating confidence intervals and p-values. Only
antigen responses values significantly larger than the correspond-
ing RPMI are represented.
Supporting Information
Figure S1 Virus growth of MVA-B and MVA-B DC6L in
HeLa cells. Monolayers of HeLa cells were infected at 0.01 PFU/
cell with WR, MVA-B or MVA-B DC6L for 0, 24, 48, and 72 h.
For comparative purposes, we used the replication-competent WR
strain. Cells were collected by centrifugation and infectious viruses
associated with the cells (intracellular) and released to the medium
(extracellular) during the course of the infection were measured by a
plaque immunostaining assay with anti-WR antibodies. Data are
from one experiment representative of two experiments.
(TIF)
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